6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting
- Naysha Becerra-Chauca,
- ,
- Alvaro Taype-Rondan
- Instituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud,
- Universidad Peruana Cayetano Heredia,
- ,
- ,
- Universidad San Ignacio de Loyola
Research Output:
Contribution to journal
Letter
Peer-reviewPublication Information
Output type
Research Output:
Contribution to journal
Letter
Peer-reviewOriginal language
EnglishPages from-to (Number of pages)
Pages e100Journal (Volume, Issue Number)
The Lancet Oncology (Volume 23, Issue 3)Publication milestones
- Published - 03/2022
Publication status
Published - 03/2022
ISSN
1470-2045Publication IDs
- Scopus: 85125308371
- PubMed: 35240085
Publication metrics
Metrics
PlumX, opens in new tab
Citations
4
Captures
6
Social media
11
Sustainable Development Goals
SDG 3 Good Health and Well